FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4283734657> ?p ?o ?g. }

• W4283734657 abstract "Venoarterial extracorporeal membrane oxygenation (VA-ECMO) has been increasingly used in patients with refractory cardiogenic shock (CS) or out-of-hospital cardiac arrest. It is difficult to perform VA-ECMO weaning, which may cause circulatory failure and death. Levosimendan is an effective inotropic agent used to maintain cardiac output, has a long-lasting effect, and may have the potential benefit for VA-ECMO weaning. The study aimed to explore the relationship between the early use of levosimendan and the rate of VA-ECMO weaning failure in patients on VA-ECMO support for circulatory failure.All patients who underwent VA-ECMO in our hospital for CS between January 2017 and December 2020 were recruited in this cohort study and divided into two groups: without and with levosimendan use. Levosimendan was used as an add-on to other inotropic agents as early as possible after VA-ECMO setting. The primary endpoint was VA-ECMO weaning success, which was defined as survival without events for 24 h after VA-ECMO withdrawl. The secondary outcomes were cardiovascular and all-cause mortality at the 30-day and 180-day follow-up periods post-VA-ECMO initialization.A total of 159 patients were recruited for our study; 113 patients were enrolled in the without levosimendan-use group and 46 patients were enrolled in the levosimendan-use group. In levosimendan-use group, the patients received levosimendan infusion within 24 h after VA-ECMO initialization. Similar hemodynamic parameters were noted between the two groups. Poorer left ventricular ejection fraction and a higher prevalence of intra-aortic balloon pumping were observed in the levosimendan group. An improved weaning rate (without vs. with: 48.7 vs. 82.6%; p < 0.001), lower in-hospital mortality rate (without vs. with: 68.1 vs. 43.5%; p = 0.007), and 180-day cardiovascular mortality (without vs. with: 75.3 vs. 43.2%; p < 0.001) were also noted. Patients administered with levosimendan also presented a lower rate of 30-day (without vs. with: 75.3 vs. 41.3%; p = 0.034) and 180-day (without vs. with: 77.0 vs. 43.2%; p < 0.001) all-cause mortality.Early levosimendan administration may contribute to increasing the success rate of VA-ECMO weaning and may help to decrease CV and all-cause mortality." @default.
• W4283734657 created "2022-07-01" @default.
• W4283734657 creator A5000060787 @default.
• W4283734657 creator A5001272448 @default.
• W4283734657 creator A5007970269 @default.
• W4283734657 creator A5009721499 @default.
• W4283734657 creator A5040587945 @default.
• W4283734657 creator A5044021292 @default.
• W4283734657 creator A5055103555 @default.
• W4283734657 creator A5068209077 @default.
• W4283734657 creator A5071791689 @default.
• W4283734657 creator A5088578056 @default.
• W4283734657 date "2022-06-30" @default.
• W4283734657 modified "2023-10-18" @default.
• W4283734657 title "Early Levosimendan Administration Improved Weaning Success Rate in Extracorporeal Membrane Oxygenation in Patients With Cardiogenic Shock" @default.
• W4283734657 cites W1996945315 @default.
• W4283734657 cites W1997993335 @default.
• W4283734657 cites W2015078144 @default.
• W4283734657 cites W2017583766 @default.
• W4283734657 cites W2029794453 @default.
• W4283734657 cites W2072332037 @default.
• W4283734657 cites W2113895692 @default.
• W4283734657 cites W2136010626 @default.
• W4283734657 cites W2142271667 @default.
• W4283734657 cites W2147088947 @default.
• W4283734657 cites W2323421413 @default.
• W4283734657 cites W2390968953 @default.
• W4283734657 cites W2427094903 @default.
• W4283734657 cites W2430498535 @default.
• W4283734657 cites W2485784764 @default.
• W4283734657 cites W2603486193 @default.
• W4283734657 cites W2755584350 @default.
• W4283734657 cites W2790544951 @default.
• W4283734657 cites W2885308056 @default.
• W4283734657 cites W2886070509 @default.
• W4283734657 cites W2890776174 @default.
• W4283734657 cites W2912881064 @default.
• W4283734657 cites W2982869217 @default.
• W4283734657 cites W2990269274 @default.
• W4283734657 cites W3026196382 @default.
• W4283734657 cites W3042260922 @default.
• W4283734657 cites W3118087224 @default.
• W4283734657 cites W3124867671 @default.
• W4283734657 cites W3158945680 @default.
• W4283734657 cites W3161949101 @default.
• W4283734657 cites W3167346234 @default.
• W4283734657 cites W3170406107 @default.
• W4283734657 cites W3177560214 @default.
• W4283734657 cites W3197050755 @default.
• W4283734657 cites W4200380308 @default.
• W4283734657 cites W4247529334 @default.
• W4283734657 cites W4293860347 @default.
• W4283734657 doi "https://doi.org/10.3389/fcvm.2022.912321" @default.
• W4283734657 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/35845047" @default.
• W4283734657 hasPublicationYear "2022" @default.
• W4283734657 type Work @default.
• W4283734657 citedByCount "5" @default.
• W4283734657 countsByYear W42837346572022 @default.
• W4283734657 countsByYear W42837346572023 @default.
• W4283734657 crossrefType "journal-article" @default.
• W4283734657 hasAuthorship W4283734657A5000060787 @default.
• W4283734657 hasAuthorship W4283734657A5001272448 @default.
• W4283734657 hasAuthorship W4283734657A5007970269 @default.
• W4283734657 hasAuthorship W4283734657A5009721499 @default.
• W4283734657 hasAuthorship W4283734657A5040587945 @default.
• W4283734657 hasAuthorship W4283734657A5044021292 @default.
• W4283734657 hasAuthorship W4283734657A5055103555 @default.
• W4283734657 hasAuthorship W4283734657A5068209077 @default.
• W4283734657 hasAuthorship W4283734657A5071791689 @default.
• W4283734657 hasAuthorship W4283734657A5088578056 @default.
• W4283734657 hasBestOaLocation W42837346571 @default.
• W4283734657 hasConcept C126322002 @default.
• W4283734657 hasConcept C155710745 @default.
• W4283734657 hasConcept C164705383 @default.
• W4283734657 hasConcept C168563851 @default.
• W4283734657 hasConcept C203092338 @default.
• W4283734657 hasConcept C2776850375 @default.
• W4283734657 hasConcept C2776858399 @default.
• W4283734657 hasConcept C2777335384 @default.
• W4283734657 hasConcept C2778198053 @default.
• W4283734657 hasConcept C2780655333 @default.
• W4283734657 hasConcept C42219234 @default.
• W4283734657 hasConcept C500558357 @default.
• W4283734657 hasConcept C71924100 @default.
• W4283734657 hasConcept C78085059 @default.
• W4283734657 hasConceptScore W4283734657C126322002 @default.
• W4283734657 hasConceptScore W4283734657C155710745 @default.
• W4283734657 hasConceptScore W4283734657C164705383 @default.
• W4283734657 hasConceptScore W4283734657C168563851 @default.
• W4283734657 hasConceptScore W4283734657C203092338 @default.
• W4283734657 hasConceptScore W4283734657C2776850375 @default.
• W4283734657 hasConceptScore W4283734657C2776858399 @default.
• W4283734657 hasConceptScore W4283734657C2777335384 @default.
• W4283734657 hasConceptScore W4283734657C2778198053 @default.
• W4283734657 hasConceptScore W4283734657C2780655333 @default.
• W4283734657 hasConceptScore W4283734657C42219234 @default.
• W4283734657 hasConceptScore W4283734657C500558357 @default.
• W4283734657 hasConceptScore W4283734657C71924100 @default.
• W4283734657 hasConceptScore W4283734657C78085059 @default.
• W4283734657 hasLocation W42837346571 @default.

• next